CACHEMIR: Personalized medicine, improves response rate to cisplatin in patients with non-small cell lung cancer

The miRNA research field is of interest for the future and is now well established that miRNAs represent new potential therapeutic targets as well as relevant diagnostic / prognostic biomarkers.

Nearly 60% of patients with non-small cell lung cancer are resistant to cisplatin, a first-line anti-cancer agent.The research teams in this project have identified a specific miRNA as a genetic factor involved in these resistances.

MiR-X is both a biomarker that can predict resistance to chemotherapy and a new therapeutic target allowing combined treatment against lung cancer.

Benefits:

• Diagnosis: Predictive biomarker of response for patients treated with cisplatin allowing a dedicated treatment. Biomarker monitoring the effectiveness of this same treatment.
• Therapeutic: Improved response rate to cisplatin in patients with non-small cell lung cancer.